663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials

BACKGROUND: LP is associated with severe CABP, rapid onset, and high morbidity/mortality. Poor outcomes in CABP have been linked to receiving inappropriate empiric therapy or delayed treatment (tx). LEF, a novel IV/oral pleuromutilin, demonstrated efficacy/safety in noninferiority studies (LEAP 1/2)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Shorr, Andrew F, Schranz, Jennifer, Goldberg, Lisa, Paukner, Susanne, Das, Anita F, Moran, Gregory J, Sandrock, Christian, File, Thomas M, Alexander, Elizabeth, Gelone, Steven P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810975/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.731
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars